Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 19 patients treated with finasteride for androgenetic alopecia developed moderate to severe depression, which resolved after stopping the medication, suggesting an association between finasteride and mood disturbances.

This study found that early-onset androgenetic alopecia in individuals of European ancestry is significantly associated with increased odds of Parkinson's disease and is influenced by specific genetic loci, including some linked to reduced fertility.

EDA2R gene linked to hair loss.

This study found that combining oral finasteride with topical minoxidil resulted in the greatest improvement in hair growth for male patients with androgenetic alopecia, compared to using any single treatment.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

TGF-β1 from dermal papilla cells suppresses hair growth, and targeting it may help treat androgenetic alopecia.

This study found that low level laser therapy with a HairMax LaserComb improved hair counts and tensile strength in patients with androgenetic alopecia, particularly in males and vertex areas.

Four genetic risk spots found for hair loss, with WNT signaling involved and a link to curly hair.

In this case series, researchers observed androgenetic alopecia in 20 prepubertal children with a strong genetic predisposition, despite the condition typically not occurring before puberty.

This review discusses the link between insulin resistance and skin conditions such as acanthosis nigricans and psoriasis, but provides no new clinical results.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This study reports that plasma rich in growth factors appeared to improve hair follicle regeneration and patient satisfaction in individuals with androgenetic alopecia, though further trials are needed.

This study explored the interaction between androgen and Wnt signaling in dermal papilla cells, targeting the effects of androgen on hair growth reduction.

This study reports that the TrichoScan method effectively measures hair growth parameters and detected significant improvements in hair counts and thickness in men with androgenetic alopecia after finasteride treatment.

This study found that hair thickness and density increased after treatment with human follicle mesenchymal stem cells and platelet rich plasma, associated with enhanced Wnt signaling and platelet derived growth factors.

This study found a significant association between androgenetic alopecia and metabolic syndrome, highlighting high-density lipoprotein cholesterol as a particularly important factor.

This case series found that adding microneedling to conventional finasteride and minoxidil therapy for androgenetic alopecia improved new hair growth and patient satisfaction in poor responders.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This review discusses telogen effluvium, a common type of hair loss, focusing on differentiation from other conditions and potential causes, but presents no new research findings.

This study found that in vitro, beard dermal papilla cells stimulated keratinocyte proliferation via androgen-dependent growth factors, while androgenetic alopecia cells released TGF-β1, inhibiting keratinocyte growth.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This study found that the prevalence of androgenetic alopecia in Chinese men was lower than in Caucasian men, similar to Korean men, and most commonly presented as type III vertex.

This study found that long-term finasteride treatment in men with androgenetic alopecia significantly increased hair weight and count compared to placebo over nearly four years.

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

This meta-analysis suggests that local injection of platelet-rich plasma for androgenic alopecia is associated with an increased number of hairs and some increase in hair thickness, though larger studies are needed for confirmation.

This report discusses cases of frontal fibrosing alopecia developing after hair transplantation for androgenetic alopecia, without presenting new clinical findings.

This study reports that a hair shedding threshold of 100 hairs or more may provide the best concordance with clinical diagnosis for distinguishing chronic telogen effluvium from androgenetic alopecia.

This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.